Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
about
Single agent versus combination chemotherapy for metastatic breast cancerRecapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture ModelsWhy don't we get more cancer? A proposed role of the microenvironment in restraining cancer progressionPhase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Tumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?Weekly docetaxel in the treatment of metastatic breast cancer.The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.Sequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message?Emerging biomarkers in breast cancer care.Eribulin.A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient.Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane.Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
P2860
Q24241459-7EBECBDF-A8D2-4D25-9CAB-D45EF7AEB790Q26797285-A31043F6-9265-4FAA-A00A-7AA5B8A41D2AQ29614274-0DB906B0-2B71-4153-81A5-99BB9E17A92FQ33394017-4646FADF-47B3-4FF2-B5E9-A7424ADEB7DCQ33395356-501AB8A2-A8DD-44EC-A745-CC0E88528E48Q34243127-30EB3A6B-88D3-40AC-9BA8-80C38DD4D896Q34611801-D442A38A-CE60-4A34-B419-A68698CCDC6EQ34870267-55086CF5-D6BD-4D84-8582-EED6023AE86AQ37052871-BF06B28A-5A14-4510-9074-17CEC704D05FQ37378233-1E70C27A-C6C3-4FDC-9787-FDFBD2F50B6CQ37385471-4201E769-9F39-4C3B-AEE4-51CDE0182324Q37779305-339AB30C-A481-41AB-B11C-EDF5E990FE38Q37902645-BDF50115-D116-4CF7-8143-9C6A7E931219Q37944440-FB5D34B9-9E92-42F1-A314-271F47A3A748Q38686625-AE35A9D4-6959-4E58-A709-E6145CAC5DF6Q39070975-EC2CC4A8-ADB8-49DD-94B4-260D9FBE7A8DQ39257653-C85A3F90-BB0D-4711-A072-D8DD11E85C34Q39775442-FAF1AEF4-B811-448A-83E6-0FFB422A86AEQ39893823-C151052E-BA92-408E-8EB3-B4DC428C73F7Q44368041-44763F78-6E9B-4D7A-970B-5AA0A69CFD29Q47568290-77252E8B-8BD3-410B-A2BC-234D5000E742Q48293335-EB376388-07A4-4389-9863-9B13BEEEFC49Q52603297-3939BD4F-2428-4020-A211-D85BF466415EQ54308667-A8E99DBF-0121-49F4-B0CD-CECF6BDC6DB7Q54949713-02109BA3-B0A5-420A-B339-A2BCCEF4691DQ55517091-98446F6A-856B-422E-A17A-DDF7693A0620
P2860
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
@ast
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
@en
type
label
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
@ast
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
@en
prefLabel
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
@ast
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
@en
P2093
P50
P1433
P1476
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer
@en
P2093
Fabienne Lebrun
Mariantonietta Colozza
Martine J Piccart
P304
P356
10.1634/THEONCOLOGIST.12-3-253
P577
2007-03-01T00:00:00Z